Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.
David Andorsky(Sheba Medical Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Sami Ibrahimi(Oklahoma State University Oklahoma City), J. Erika Haydu(Brigham and Women's Hospital), Thomas Doerr(AbbVie (United States)), Kristin Conte(AbbVie (United States)), Bradley W. Lash(SUNY Upstate Medical University), Kojo Osei-Bonsu(AbbVie (United States)), Ameet Patel(Oncology Hematology Care), Fernando Manuel Vargas Madueno(Moffitt Cancer Center), Seema Naik(CHRISTUS Transplant Institute), Yang Bai(AbbVie (United States)), Mariana Sacchi(Genmab (United States)), Rakhee Vaidya(Atrium Health Wake Forest Baptist), Ralph V. Boccia(Center for Cancer and Blood Disorders), Mark Fesler(St. Luke's Hospital), Mitul Gandhi(Virginia Cancer Specialists), Christina Y. Lee(Memorial Sloan Kettering Cancer Center)
Cited by 2
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761